FDA issued guidance primarily intended to support drug development for rare disease treatments. It describes frequently encountered issues with sponsors and what can be done to address them during early development and in pre-IND meetings.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
